Press Releases

Iterum Therapeutics Regains Compliance with Nasdaq Bid Price Rule

Sep 1, 2022

Iterum Therapeutics Announces Date of 1-for-15 Reverse Share Split

Aug 16, 2022

Iterum Therapeutics Reports Second Quarter 2022 Financial Results

Aug 12, 2022

Iterum Therapeutics Announces Special Protocol Assessment (SPA) Agreement With the FDA

Jul 11, 2022

Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 6, 2022

Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jun 14, 2022

Iterum Therapeutics Reports First Quarter 2022 Financial Results

May 13, 2022

Iterum Therapeutics Provides Regulatory Update

May 11, 2022

Iterum Therapeutics Presented Data at the 32nd European Congress of Clinical Microbiology and Infectious Diseases

Apr 25, 2022

Iterum Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

Mar 28, 2022